Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PML
REST API REST API
Homo sapiens
PML is differentially expressed in 350 experiments: 182 organism parts: lung, heart, ... (180 more);, 275 disease states: normal, breast carcinoma, ... (273 more);, 99 cell types 511 cell lines 52 compound treatments and 89 other conditions.
Synonyms MYL, TRIM19, RNF71
Orthologs PML (Bos taurus)   ENSGALG00000001398 (Gallus gallus)   ENSGALG00000001478 (Gallus gallus)   Pml (Mus musculus)   F1M589_RAT (Rattus norvegicus)   XM_849154.1 (Canis familiaris)   ENSCAFG00000017858 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, cytosol, negative regulation of cell growth, DNA binding, protein stabilization, negative regulation of mitotic cell cycle, maintenance of protein location in nucleus, endoplasmic reticulum, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytokine-mediated signaling pathway, cytoplasm, DNA damage response, signal transduction resulting in induction of apoptosis, intracellular, negative regulation of cell proliferation, membrane, protein targeting, cell cycle arrest, metal ion binding, activation of caspase activity, transforming growth factor beta receptor signaling pathway, insoluble fraction, protein complex assembly, response to hypoxia, nuclear matrix, induction of apoptosis, transcription coactivator activity, DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis, nucleus, protein heterodimerization activity, cell fate commitment, endosome, protein homodimerization activity, SMAD binding, nucleoplasm, response to gamma radiation, nucleolus, nuclear membrane, zinc ion binding, ubiquitin protein ligase binding, SUMO binding, response to cytokine stimulus, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, extrinsic to endoplasmic reticulum membrane, cell aging, negative regulation of angiogenesis, negative regulation of translation in response to oxidative stress, PML body organization, negative regulation of telomerase activity, negative regulation of telomere maintenance via telomerase, endoplasmic reticulum calcium ion homeostasis, response to virus, early endosome membrane, positive regulation of defense response to virus by host, interspecies interaction between organisms, PML body, branching involved in mammary gland duct morphogenesis, cobalt ion binding, regulation of MHC class I biosynthetic process, positive regulation of histone deacetylation, retinoic acid receptor signaling pathway, myeloid cell differentiation, common-partner SMAD protein phosphorylation, regulation of protein phosphorylation, interferon-gamma-mediated signaling pathway, SMAD protein import into nucleus, regulation of calcium ion transport into cytosol, negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
InterPro Term Znf_RING, Znf_B-box, DUF3583
UniProt Accession Q9UE85, P29590, Q05835, E9PBR7, F8W9X2
Search EB-eye ENSG00000140464
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
HepG2
3
E-GEOD-21154, E-MTAB-37, E-GEOD-7307
BT474
2
E-MTAB-37, E-MTAB-62
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-TABM-420, E-GEOD-14990
505 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21750, ... (49 experiments)

Factor Value U/D Experiments
mononuclear cell
2
E-GEOD-6053, E-MEXP-66
testis - germ cell
2
E-TABM-145, E-AFMX-5
CD105+ endothelial
2
2
E-TABM-145, E-AFMX-5
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-TABM-145, E-AFMX-5
CD56+ NK cells
2
E-TABM-145, E-AFMX-5
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-12254, ... (76 experiments)

Factor Value U/D Experiments
Huntington's disease
3
E-GEOD-1751, E-GEOD-3790, E-AFMX-6
dermatomyositis
3
E-MTAB-62, E-GEOD-5370, E-GEOD-1551
benign prostatic hyperplasia
3
E-MEXP-2034, E-GEOD-7307, E-MEXP-1243
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
synovial sarcoma
2
E-GEOD-6481, E-MTAB-37
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
269 more value(s).


Compound treatment

studied in E-GEOD-5542, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (34 experiments)

Factor Value U/D Experiments
placebo
2
E-MEXP-1335, E-MEXP-1327
AMP
1
1
E-MEXP-2285
8-(3-chlorostyryl) caffeine
1
1
E-GEOD-995
vanadium
1
E-GEOD-2111
control - untreated
1
E-GEOD-7216
filtered air
1
E-TABM-127
46 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-6236, E-GEOD-4667, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22541, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-TABM-440, E-GEOD-837, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, E-GEOD-980, ... (8 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-22541, E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-TABM-43, ... (8 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.354 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM